Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course.
|
31778911 |
2020 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV).
|
31711337 |
2020 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF).
|
30962501 |
2020 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unfortunately, ruxolitinib, the JAK1/2 inhibitor approved by FDA and EMEA for PMF, ameliorates symptoms but does not improve the natural course of the disease, and the cure of PMF is still an unmet clinical need.
|
31749302 |
2020 |
Primary Myelofibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Only JAK1/2 inhibitor ruxolitinib largely activated ERK1/2 signaling in essential thrombocythemia and PMF (up to 4.6 fold), with a more prominent activation in JAK2V617F positive granulocytes.
|
30571852 |
2019 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis.
|
30675650 |
2019 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
|
30997748 |
2019 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms.
|
31201513 |
2019 |
Primary Myelofibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression.
|
29616317 |
2018 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed 626 patients with MPN, including 69 with myelofibrosis receiving JAK1/2 inhibitors for lymphoma development.
|
29907599 |
2018 |
Primary Myelofibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2.
|
29515114 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this report, we discuss the clinical history, pathological evaluation, and genomics findings in a patient with JAK2-positive myelofibrosis who developed a secondary myelodysplasia after hematopoietic stem cell transplantation and JAK1/2 inhibitor treatment.
|
30097215 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012.
|
30043249 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib, a potent oral JAK1/JAK2 inhibitor remains the only Food and Drug Administration (FDA)-approved medicinal therapy for the treatment of MF.
|
29480036 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is a JAK1/2 inhibitor that may control myelofibrosis (MF)-related splenomegaly and symptoms and can be prescribed regardless of age.
|
30010187 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly related to myelofibrosis (MF).
|
29189896 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert commentary: The most mature advances in treatment of myelofibrosis are the development of second-generation JAK1/2 inhibitors and improvements in expanding access to donors for transplantation.
|
30324817 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Momelotinib is a Janus kinase 1/2 inhibitor in clinical development for the treatment of myelofibrosis.
|
29283448 |
2018 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
|
27785927 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of note, ruxolitinib, a JAK1/2 inhibitor approved for the treatment of MF, had no inhibitory activity on this pathway.
|
28188131 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials.
|
27740634 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we review novel therapeutic options for MF including the new JAK1/2 inhibitors, ruxolitinib based combination approaches as well as novel therapeutic agents.
|
28395559 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF).
|
28260257 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The only approved JAK2 inhibitor for myelofibrosis is the dual JAK1 and JAK2 inhibitor, ruxolitinib.
|
28602585 |
2017 |
Primary Myelofibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib, a JAK1/2 inhibitor, is currently the only drug approved for the treatment of patients with intermediate or high risk MF.
|
27882812 |
2017 |